These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8067196)

  • 1. [Clinical applications of erythropoietin].
    Robak T
    Acta Haematol Pol; 1994; 25(2 Suppl 1):112-23. PubMed ID: 8067196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin therapy in the surgical setting and applications in oncology.
    Goodnough LT
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):98-102. PubMed ID: 1928088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Physiology of eryhtropoietin and its therapeutic use].
    Casadevall N
    Ann Pharm Fr; 1996; 54(4):151-6. PubMed ID: 8881101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of recombinant human erythropoietin (rHuEpo) in humans.
    Adamson JW; Eschbach JW
    Cancer Surv; 1990; 9(1):157-67. PubMed ID: 2276112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A; Arai K
    Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Erythropoietin--physiology and therapeutic potentialities].
    Möllmann M
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1992 Dec; 27(8):461-8. PubMed ID: 1489869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemical structure, biotechnical production and clinical use of recombinant erythropoietin].
    Fandrey JK; Jelkmann WE
    Z Gesamte Inn Med; 1992 Jun; 47(6):231-8. PubMed ID: 1642021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin-- measurement and clinical applications.
    Marsden JT
    Ann Clin Biochem; 2006 Mar; 43(Pt 2):97-104. PubMed ID: 16536911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-related anemia: its causes and characteristics.
    Spivak JL
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):3-8. PubMed ID: 8202724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin: mechanisms of action and indications for treatment.
    Vreugdenhil G; Frenken LA; Koene RA
    Neth J Med; 1993 Jun; 42(5-6):187-202. PubMed ID: 8377877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin: biology and clinical use.
    Graber SE; Krantz SB
    Hematol Oncol Clin North Am; 1989 Sep; 3(3):369-400. PubMed ID: 2561121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of EPOGEN for treatment of anemia associated with chronic renal failure.
    Erlich L
    Crit Care Nurs Clin North Am; 1990 Mar; 2(1):101-13. PubMed ID: 2357306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human recombinant erythropoietin: progress in clinical development.
    Kubiak W; Karwacki M; Mazur I
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():39-50. PubMed ID: 8192531
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antibodies against human recombinant erythropoietin: an unusual cause of erythropoietin resistance].
    Virón B; Kolta A; Kiladjian JJ; Mignon F; Mayeux P; Casadevall N
    Nephrologie; 2002; 23(1):19-22. PubMed ID: 11887573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study.
    Vannucchi AM; Bosi A; Linari S; Guidi S; Longo G; Lombardini L; Mariani MP; Saccardi R; Laszlo D; Rossi Ferrini P
    Haematologica; 1997; 82(1):53-6. PubMed ID: 9107083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anemia in AIDS: the problem to avoid. Human recombinant erythropoietin in the treatment of HIV positive patients].
    Karwacki M; Ochocka M; Kubiak W
    Przegl Epidemiol; 1994; 48(4):441-7. PubMed ID: 7597181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.